Americans are buying so much Ozempic that it's shifting the economy of Denmark, where the drug's maker Novo Nordisk is based.Novo, Europe's second most valuable listed company behind LVMH, is riding a wave of huge demand for its and weight-loss drugs Ozempic and Wegovy, sending the company's earnings to record highs. Analysts expect Novo's weight-loss drug sales to hit $6.1 billion this year, and to reach nearly $15 billion annually in 2027, according to polling from FactSet.
Load More
Load More